# A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

> **NCT03196284** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 26 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** Concizumab
- **DRUG:** Eptacog alfa

## Key facts

- **NCT ID:** NCT03196284
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-10
- **Primary completion:** 2018-09-19
- **Final completion:** 2020-01-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196284, "A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03196284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*